MCRB - Seres Therapeutics Inc. (MCRB) Q4 2023 Earnings Call Transcript
2024-03-05 15:33:08 ET
Seres Therapeutics, Inc. (MCRB)
Q4 2023 Earnings Call Transcript
March 05, 2024, 08:30 AM ET
Company Participants
Rob Windsor - IR
Eric Shaff - CEO
Terri Young - CCO & CSO
Lisa von Moltke - CMO
David Arkowitz - CFO
Dave Ege - CTO
Matthew Henn - Chief Scientific Officer
Conference Call Participants
Jeff Jones - Oppenheimer
John Newman - Canaccord
Tess Romero - JPMorgan
Peyton Bohnsack - TD Cowen
Chris Shibutani - Goldman Sachs
Keay Nakae - Chardan
Presentation
Operator
Ladies and gentlemen, good morning. My name is Abby, and will be your conference operator today. At this time, I would like to welcome everyone to the Seres Therapeutics Fourth Quarter 2023 Earnings Conference Call. Today's conference is being recorded and all lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. And I will now turn the conference over to Rob Windsor of Investor Relations. You may begin.
Rob Windsor
Thank you and good morning. Our press release for the company's fourth quarter 2023 financial results became available at 7:00 a.m. Eastern Time this morning and can be found on the Investors and News section of the company's website.
I'd like to remind you that we'll be making forward-looking statements, including the availability of cash to fund operations, the potential sales for VOWST including our ability to achieve sales targets and milestones, the timing and results of clinical studies and other statements, which are not historical facts. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties, which are discussed under the Risk Factors section of our recent SEC filings. Any forward-looking statements made on today's call represent our views as of today only. We may update these statements in the future, but we disclaim any obligation to do so.
On today's call with prepared remarks, I'm joined by Eric Shaff, Seres' Chief Executive Officer; Dr. Terri Young, Chief Commercial and Strategy Officer; Dr. Lisa von Moltke, Chief Medical Officer; and David Arkowitz, Chief Financial Officer. In addition to that, Dr. Matthew Henn, Chief Scientific Officer, and Dr. Dave Ege, Chief Technology Officer, will also be available to address questions....
Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript